An Extension Study to Evaluate 24 Months of Standard-of-Care Osteoporosis Management Following Completion of 18 Months of BA058 (Abaloparatide) or Placebo Treatment in Protocol BA058-05-003

Trial Profile

An Extension Study to Evaluate 24 Months of Standard-of-Care Osteoporosis Management Following Completion of 18 Months of BA058 (Abaloparatide) or Placebo Treatment in Protocol BA058-05-003

Completed
Phase of Trial: Phase III

Latest Information Update: 10 Sep 2017

At a glance

  • Drugs Abaloparatide (Primary) ; Alendronic acid
  • Indications Fracture; Postmenopausal osteoporosis
  • Focus Adverse reactions; Registrational
  • Acronyms ACTIVExtend
  • Sponsors Radius Health Inc.
  • Most Recent Events

    • 10 Sep 2017 According to a Radius Health media release, results were presented at the American Society for Bone and Mineral Research (ASBMR) Annual Meeting 2017.
    • 10 Aug 2017 Results published in a Radius Health Inc. Media Release.
    • 03 Aug 2017 According to a Radius Health media release, additional results from this trial will be presented at the American Society for Bone and Mineral Research (ASBMR) Annual Meeting 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top